ARVN - アルビナス （Arvinas Inc.）

Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Wednesday, 10/26/22, with the stock price up by 11.98% to the previous day’s close as strong demand from buyers drove the stock to $49.44. Actively observing the price movement in the last trading, the stock closed the session at $44.15, falling within a range of $44.31 and … Arvinas Inc. (NASDAQ: ARVN) Is An Exciting Stock To Watch. Read More »

In Wednesday’s session, Arvinas Inc. (NASDAQ:ARVN) marked $49.44 per share, up from $44.15 in the previous session. While Arvinas Inc. has overperformed by 11.98%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARVN fell by -42.01%, with highs and lows ranging from $97.33 to $34.90, whereas […]

Arvinas Inc. (NASDAQ:ARVN) concluded the trading at $42.48 on Friday, October 14 with a fall of -0.89% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $42.86 and 5Y monthly beta was reading 1.98 with its price kept floating in the range … Arvinas Inc. (ARVN) Forecast: Revisiting The Past To Gain Insights For The Future Read More »

Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 09/16/22, with the stock price down by -2.99% to the previous day’s close as strong demand from buyers drove the stock to $47.41. Actively observing the price movement in the last trading, the stock closed the session at $48.87, falling within a range of $46.85 and … Selling Your Arvinas Inc. (NASDAQ: ARVN) Stock? Here’s What You Need To Know Read More »

The following slide deck was published by Arvinas, Inc.

NEW HAVEN, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in three upcoming investor conferences:

Shares of Arvinas have nearly tripled from its IPO price point of $16 back in 2018. See why I still don''t recommend buying ARVN stock.

According to Benzinga Pro data, Arvinas (NASDAQ: ARVN ) reported Q2 sales of $31.30 million. Earnings fell to a loss of $70.00 million, resulting in a 10.41% decrease from last quarter. In Q1, Arvinas brought in $24.20 million in sales but lost $63.40 million in earnings. What Is Return On Invested Capital? Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company''s ROIC. A higher ROIC is generally representative of successful growth of a company and is a … Full story available on Benzinga.com

Piper Sandler has started coverage of Arvinas (ARVN) with a buy rating saying that Sanofi (SNY) recent discontinuation of amcenestrant for breast cancer will benefit the biotech.The…

In last trading session, Arvinas Inc. (NASDAQ:ARVN) saw 0.4 million shares changing hands with its beta currently measuring 2.00. Company’s recent per share price level of $54.46 trading at -$0.08 or -0.15% at ring of the bell on the day assigns it a market valuation of $2.69B. That closing price of ARVN’s stock is at … Arvinas Inc. (NASDAQ:ARVN) Lost -1.75% In A Week: What’s Driving The Stock? Read More »

In last trading session, Arvinas Inc. (NASDAQ:ARVN) saw 0.44 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $66.42 trading at -$3.74 or -5.33% at ring of the bell on the day assigns it a market valuation of $3.39B. That closing price of ARVN’s stock is at … Arvinas Inc. (NASDAQ:ARVN)’s 12-Month Price Target Currently Stands At $170.00 Read More »

Arvinas (NASDAQ: ARVN ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 1 0 0 0 0 These 6 analysts have an average price target of $102.33 versus the current price of Arvinas at $70.83, implying upside. Below is a summary of how these 6 analysts rated Arvinas over the past 3 months. The greater the number of bullish ratings, the more positive analysts … Full story available on Benzinga.com

Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 04/01/22, with the stock price up by 4.04% to the previous day’s close as strong demand from buyers drove the stock to $70.02. Actively observing the price movement in the last trading, the stock closed the session at $67.30, falling within a range of $67.40 and … Is Arvinas Inc. (NASDAQ: ARVN) A Good Pick For New Investors Now? Read More »

Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 03/11/22, with the stock price down by -0.53% to the previous day’s close as strong demand from buyers drove the stock to $68.21. Actively observing the price movement in the last trading, the stock closed the session at $68.57, falling within a range of $67.685 and … Things To Consider Before Buying Arvinas Inc. (NASDAQ: ARVN) Read More »

Arvinas (NASDAQ: ARVN ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Arvinas has an average price target of $114.0 with a high of $157.00 and a low of $91.00. Below is a summary of how these 4 analysts rated Arvinas over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … Full story available on Benzinga.com